[{"indications": "Indications\u00a0see notes above; ankylosing spondylitis,\r\npsoriatic arthritis, polyarticular course juvenile idiopathic arthritis,\r\nrheumatoid arthritis (%s\n(From ETANERCEPT: British National Formulary)\nETANERCEPT)", "name": "ETANERCEPT", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.5 Preparations for eczema and psoriasis", "13.5.3 Drugs affecting the immune response", "Cytokine modulators"], "cautions": "Cautions\u00a0section 10.1.3", "side-effects": "Side-effects\u00a0section 10.1.3", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201652.htm", "doses": ["By subcutaneous injection, plaque psoriasis,\r\n25\u00a0mg twice weekly or 50\u00a0mg once weekly for up to 24 weeks; discontinue\r\nif no response after 12 weeks; child 6\u201318 years, 800\u00a0micrograms/kg (max. 50\u00a0mg) once weekly for up to\r\n24 weeks; discontinue if no response after 12 weeks"], "pregnancy": "Pregnancy\u00a0section 10.1.3"}, {"indications": "Indications\u00a0 see under Cytokine Modulators above", "name": "ETANERCEPT - DRUGS THAT SUPPRESS THE RHEUMATIC DISEASE PROCESS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.3 Drugs that suppress the rheumatic disease process", "Cytokine modulators"], "cautions": "Cautions\u00a0predisposition to infection (avoid if predisposition to septicaemia); significant\r\nexposure to herpes zoster virus\u2014interrupt treatment\r\nand consider varicella\u2013zoster immunoglobulin; hepatitis\r\nB virus\u2014monitor for active infection; monitor\r\nfor worsening hepatitis C infection; children should\r\nbe brought up to date with current immunisation schedule (section 14.1) before initiating therapy; heart failure (risk of exacerbation); history or increased\r\nrisk of demyelinating disorders; history or development of malignancy; monitor for skin cancer before and during treatment, particularly\r\nin those at risk (including patients with psoriasis or a history of\r\nPUVA treatment); history of blood disorders; diabetes mellitus; interactions: Appendix 1 (etanercept)Tuberculosis\u00a0Patients should be evaluated\r\nfor tuberculosis before treatment. Active tuberculosis\r\nshould be treated with standard treatment (section 5.1.9) for at least 2 months before\r\nstarting etanercept. Patients who have previously received\r\nadequate treatment for tuberculosis can start etanercept but should\r\nbe monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not\r\ntreated adequately, chemoprophylaxis should ideally be completed before\r\nstarting etanercept. In patients at high\r\nrisk of tuberculosis who cannot be assessed by tuberculin skin test,\r\nchemoprophylaxis can be given concurrently with etanercept. Patients should be advised to seek medical attention\r\nif symptoms suggestive of tuberculosis (e.g. persistent cough, weight\r\nloss, and fever) developBlood disorders\u00a0Patients should be\r\nadvised to seek medical attention if symptoms suggestive of blood\r\ndisorders (such as fever, sore throat, bruising, or bleeding) develop", "side-effects": "Side-effects\u00a0see under Cytokine Modulators; also less commonly interstitial lung disease,\r\nskin cancer, uveitis, rash, new onset or worsening psoriasis; rarely demyelinating disorders, seizures, lymphoma, Stevens-Johnson\r\nsyndrome, vasculitis; very rarely toxic epidermal\r\nnecrolysis; also reported appendicitis, gastritis,\r\noesophagitis, inflammatory bowel disease, vomiting, diabetes mellitus,\r\nmalignancy (including solid tumours and leukaemia), macrophage activation\r\nsyndrome, and cutaneous ulcer", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128236.htm", "doses": ["By subcutaneous injection, rheumatoid\r\narthritis, psoriatic arthritis, ankylosing spondylitis, adult over 18 years, 25\u00a0mg twice weekly or 50\u00a0mg once weekly", "Active polyarticular juvenile idiopathic arthritis, child 2\u201317 years, 400\u00a0micrograms/kg (max. 25\u00a0mg)\r\ntwice weekly, with an interval of 3\u20134 days between doses; consider\r\ndiscontinuation if no response after 4 months"], "pregnancy": "Pregnancy\u00a0avoid\u2014limited information available; manufacturer\r\nadvises effective contraception required during treatment and for\r\n3 weeks after last dose"}, {"indications": "Indications\u00a0see notes above; ankylosing spondylitis,\r\npsoriatic arthritis, polyarticular course juvenile idiopathic arthritis,\r\nrheumatoid arthritis (%s\n(From ETANERCEPT: British National Formulary)\nETANERCEPT)", "name": "ETANERCEPT - DRUGS AFFECTING THE IMMUNE RESPONSE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.5 Preparations for eczema and psoriasis", "13.5.3 Drugs affecting the immune response", "Cytokine modulators"], "cautions": "Cautions\u00a0section 10.1.3", "side-effects": "Side-effects\u00a0section 10.1.3", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201652.htm", "doses": ["By subcutaneous injection, plaque psoriasis,\r\n25\u00a0mg twice weekly or 50\u00a0mg once weekly for up to 24 weeks; discontinue\r\nif no response after 12 weeks; child 6\u201318 years, 800\u00a0micrograms/kg (max. 50\u00a0mg) once weekly for up to\r\n24 weeks; discontinue if no response after 12 weeks"], "pregnancy": "Pregnancy\u00a0section 10.1.3"}]